GLIFEMPA-LIN TABS 30’S

Glifempa-Lin Tablets (30’s)

Glifempa-Lin is a combination oral antidiabetic medication containing Empagliflozin (SGLT2 inhibitor) and Linagliptin (DPP-4 inhibitor). It is used to improve glycemic control in adults with type 2 diabetes mellitus.

Key Features:

• Dual-action formula: Empagliflozin reduces glucose reabsorption in the kidneys, while Linagliptin increases insulin secretion and decreases glucagon levels.

• Once-daily oral dosing for simplicity and better adherence.

• Helps in reducing HbA1c, fasting, and postprandial glucose levels.

• Weight-neutral or mildly reducing; low risk of hypoglycemia when used alone.

• May offer added cardiovascular and renal benefits in high-risk patients.

Indications:

• Management of type 2 diabetes mellitus in adults as an adjunct to diet and exercise.

• For patients inadequately controlled on either Empagliflozin or Linagliptin alone or in combination with other antidiabetic drugs.

Dosage & Administration:

• One tablet once daily, with or without food.

• Dosage to be individualized based on clinical response and renal function.

• Regular blood glucose and kidney function monitoring is advised.

Precautions:

• Not for type 1 diabetes or diabetic ketoacidosis.

• Monitor for signs of urinary/genital infections and pancreatitis.

• Use cautiously in renal impairment.

• Inform healthcare provider about all medications in use.

Possible Side Effects:

• Urinary tract or genital infections

• Headache, nausea, or mild gastrointestinal symptoms

• Rare: ketoacidosis or pancreatitis

• Low risk of hypoglycemia unless combined with insulin or sulfonylureas

Storage:

• Store below 25°C in a dry place, away from direct sunlight.

• Keep out of reach of children.